Alcon (ALC)

• Market cap: $43.3B
• 1 day: -1.99%
• 5 days: -0.44%
• 1 month: -4.16%
• 3 months: -2.22%
• 6 months: 2.43%
• Year to date: 4.95%
• 1 year: -0.59%
• 5 years: 41.88%
• 10 years: 50.90%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Employees: 25,599

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 15 (+3) [Q1 2025]

5% more capital invested

Capital invested by funds: $22.2B [Q4 2024] → $23.4B (+$1.17B) [Q1 2025]

9% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 70

2% less funds holding

Funds holding: 645 [Q4 2024] → 633 (-12) [Q1 2025]

5.38% less ownership

Funds ownership: 53.07% [Q4 2024] → 47.69% (-5.38%) [Q1 2025]

11% less repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 217

33% less call options, than puts

Call options by funds: $226M | Put options by funds: $340M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $108 23% upside
• Avg. target: $113 28% upside
• High target: $120 37% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Needham David Saxon	26% upside $110	Buy Reiterated	14 May 2025
Keybanc Brett Fishbin	28% upside $112	Overweight Maintained	31 Mar 2025
Mizuho Anthony Petrone	37% upside $120	Outperform Maintained	28 Mar 2025
Baird Jeff Johnson	23% upside $108	Outperform Maintained	27 Feb 2025